Is There a Role for 5α-Reductase Inhibitors in Transgender Individuals?

    Michael S. Irwig
    Image of study
    TLDR 5α-reductase inhibitors like finasteride may not be effective or safe for transgender individuals, and more research is needed.
    The article from 2020 examines the use of 5α-reductase inhibitors like finasteride and dutasteride in transgender individuals. It notes that while 30% of 166 transfeminine individuals at a clinic in Albany, NY were prescribed finasteride, its effectiveness in reducing androgens and preventing balding is not well-supported by scientific evidence and may even raise testosterone levels. In transmasculine individuals, a study of 10 subjects showed finasteride could improve hair loss, but its use is not routinely recommended due to potential interference with virilization and varying concerns about hair loss. Additionally, the safety of these drugs in transgender populations is not well-established, with some adverse effects reported in cisgender men. The article emphasizes the need for more research to determine the efficacy and safety of 5α-reductase inhibitors in transgender individuals before they can be routinely recommended.
    Discuss this study in the Community →

    Research cited in this study

    10 / 10 results

    Related Community Posts Join

    6 / 161 results
      Can I still save my hairline at age of 15?

      community Can I still save my hairline at age of 15?

      in General  476 upvotes 2 weeks ago
      A 15-year-old is concerned about hair loss, possibly at Norwood 2 or 3, and is using shampoos and conditioners recommended by a trichologist. Suggestions include considering topical minoxidil and consulting a doctor about topical anti-DHT treatments like finasteride or RU58841, but avoiding 5-alpha-reductase inhibitors at this age.

      community EU Shouldn't Ban Fin & Dut: PFS is NOT REAL.

      in Research/Science  11 upvotes 11 months ago
      Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

    Related Research

    3 / 3 results